Showing results (91-100 of 136) with videos related to
Sort By:
Pageof 14
BMC Cancer|May 30, 2021
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE studyStéphane Dalle, Laurent Mortier, Pippa Corrie, et al.Genes & Development|February 27, 2019
BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanomaKatharine Herbert, Romuald Binet, Jean-Philippe Lambert, et al.Journal of Clinical Pharmacology|December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenibA Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.British Journal of Cancer|March 16, 2021
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profilesWeiyu Ye, Anna Olsson-Brown, Robert A Watson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumorsSuzanne Leijen, Mark R Middleton, Patricia Tresca, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human StudyDejan Juric, Jordi Rodon, Josep Tabernero, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic MelanomaMark R Middleton, Cheryl McAlpine, Victoria K Woodcock, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2020
sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older PatientsMitchell E Fane, Brett L Ecker, Amanpreet Kaur, et al.Proceedings of the National Academy of Sciences of the United States of America|January 12, 2023
Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biologyNadia Bannoud, Juan C Stupirski, Alejandro J Cagnoni, et al.The Lancet. Oncology|October 12, 2024
Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysisAshley Jackson, Pradeep S Virdee, Sharon Tonner, et al.Pageof 14